Results · Apr-Jun 2026
Natco Pharma Q1 FY27 results
Sales fell 45% to ₹735 crore from ₹1,329 crore in Apr-Jun 2025.
Operating profit fell 67% to ₹187 crore, an operating margin of 25.4% (down 17.6 points from a year ago).
Net profit fell 57% to ₹207 crore from ₹480 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −1%, net profit −23%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 735.2 | 1,329 | −45% |
| Operating profit (EBITDA) | 186.5 | 571.0 | −67% |
| Operating margin | 25.4% | 43.0% | −17.6 pts |
| Net profit | 206.5 | 480.3 | −57% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue fell to ₹794 crore from ₹1,391 crore from a year earlier due to lower Lenalidomide, but EBITDA margin improved to 30.9%. PAT was ₹207 crore; management guides full-year revenue of ₹3,300–3,400 crore & PAT of ₹750 crore.
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.